VYGR vs. EDIT, LXEO, FATE, TSHA, OCGN, TCRX, ALLO, CCCC, REPL, and ALEC
Should you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Editas Medicine (EDIT), Lexeo Therapeutics (LXEO), Fate Therapeutics (FATE), Taysha Gene Therapies (TSHA), Ocugen (OCGN), TScan Therapeutics (TCRX), Allogene Therapeutics (ALLO), C4 Therapeutics (CCCC), Replimune Group (REPL), and Alector (ALEC). These companies are all part of the "biological products, except diagnostic" industry.
Editas Medicine (NASDAQ:EDIT) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
Voyager Therapeutics has higher revenue and earnings than Editas Medicine. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Editas Medicine has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.
71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 1.9% of Editas Medicine shares are held by company insiders. Comparatively, 4.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Voyager Therapeutics had 6 more articles in the media than Editas Medicine. MarketBeat recorded 9 mentions for Voyager Therapeutics and 3 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.71 beat Voyager Therapeutics' score of 0.30 indicating that Voyager Therapeutics is being referred to more favorably in the news media.
Voyager Therapeutics has a net margin of -2.56% compared to Voyager Therapeutics' net margin of -239.36%. Editas Medicine's return on equity of -1.28% beat Voyager Therapeutics' return on equity.
Editas Medicine presently has a consensus target price of $13.90, indicating a potential upside of 140.48%. Voyager Therapeutics has a consensus target price of $18.00, indicating a potential upside of 120.32%. Given Voyager Therapeutics' higher probable upside, equities research analysts clearly believe Editas Medicine is more favorable than Voyager Therapeutics.
Voyager Therapeutics received 77 more outperform votes than Editas Medicine when rated by MarketBeat users. Likewise, 67.32% of users gave Voyager Therapeutics an outperform vote while only 53.83% of users gave Editas Medicine an outperform vote.
Summary
Voyager Therapeutics beats Editas Medicine on 12 of the 17 factors compared between the two stocks.
Get Voyager Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Voyager Therapeutics Competitors List
Related Companies and Tools
